Anticoagulant Therapy in a Congenital Antithrombin III (ATIII)-Deficient Patient with Chronic Renal Failure Undergoing Regular Hemodialysis
- 1 January 1991
- journal article
- case report
- Published by Taylor & Francis in Biomaterials, Artificial Cells and Immobilization Biotechnology
- Vol. 19 (1) , 185-191
- https://doi.org/10.3109/10731199109117825
Abstract
We describe a 43-year-old male patient with congenital antithrombin III deficiency requiring hemodialysis due to extension of venous thrombus from recurrent deep vein thrombosis. During dialysis with adequate heparinization, the patient often revealed clot formation in the extracorporeal circuit resulting in unexpected discontinuation of dialysis. When either a combination of antithrombin III concentrate + heparin or the newly developed synthetic antithrombin preparation, MD805, was administered during dialysis, he could be uneventfully dialyzed with either of the two regimens.Keywords
This publication has 4 references indexed in Scilit:
- Determination of Human Thrombin-Antithrombin III Complex in Plasma with an Enzyme-Linked Immunosorbent AssayThrombosis and Haemostasis, 1988
- Plasma antithrombin activity of MD 805 determined by chromogenic substrate during hemodialysis.Blood & Vessel, 1987
- Effect of a new anticoagulant (MD 805) on platelet activation in the hemodialysis circuitThrombosis Research, 1986